Pierre Robin Sequence Outcome Assessment Multi Institutional Study

首次发布于 2015 年 5 月 4 日

Early Treatment Outcomes in Pierre-Robin-Like Phenotype

计划入组 50 人 · 首次发布于 2014 年 10 月 16 日

Effect of Oral Enteral Nutrition in Pierre Robin Syndrome

计划入组 50 人 · 首次发布于 2024 年 3 月 12 日

farnesyl transferase inhibitors (Pierre Fabre)

Melanoma vaccine(Pierre Fabre SA)

Anti-JAM-A mAb (Pierre Fabre)

PIERRE FABRE PHARMACEUTICALS, INC.

United States

PIERRE FABRE MEDICAMENT

India

Pierre Fabre Ltd.

United Kingdom

Pierre Fabre's Tabelecleucel Shows 47.7% Response Rate in Phase 3 Trial for Rare Post-Transplant Cancer

European Commission Approves Encorafenib and Binimetinib Combination for BRAF V600E-Mutant NSCLC

Pierre Fabre Acquires Global Rights to Next-Generation EGFR Inhibitors for NSCLC Treatment